AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
The inspection concluded with zero Form 483 observations
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The company will provide the necessary response to USFDA within stipulated 15 days
Subscribe To Our Newsletter & Stay Updated